Brokerages expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will post $4.54 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The highest sales estimate is $7.14 million and the lowest is $1.07 million. BioCryst Pharmaceuticals posted sales of $1.45 million in the same quarter last year, which suggests a positive year over year growth rate of 213.1%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $13.93 million for the current year, with estimates ranging from $10.47 million to $16.34 million. For the next financial year, analysts forecast that the firm will report sales of $39.43 million, with estimates ranging from $10.00 million to $87.44 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The company had revenue of $1.45 million for the quarter, compared to analyst estimates of $2.52 million. BioCryst Pharmaceuticals had a negative return on equity of 371.33% and a negative net margin of 1,091.44%.
BCRX opened at $2.45 on Friday. BioCryst Pharmaceuticals has a 12 month low of $2.35 and a 12 month high of $9.95. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The stock has a market cap of $262.84 million, a P/E ratio of -2.49 and a beta of 1.95. The stock’s 50 day moving average price is $2.89 and its 200 day moving average price is $4.56.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG boosted its stake in BioCryst Pharmaceuticals by 331.0% during the 2nd quarter. UBS Group AG now owns 2,202,794 shares of the biotechnology company’s stock valued at $8,349,000 after purchasing an additional 1,691,681 shares in the last quarter. University of Notre Dame DU Lac bought a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at $1,854,000. Voloridge Investment Management LLC boosted its stake in BioCryst Pharmaceuticals by 942.0% during the 2nd quarter. Voloridge Investment Management LLC now owns 130,300 shares of the biotechnology company’s stock valued at $494,000 after purchasing an additional 117,795 shares in the last quarter. Nuveen Asset Management LLC bought a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at $3,101,000. Finally, UBS Asset Management Americas Inc. boosted its stake in BioCryst Pharmaceuticals by 7.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 65,958 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 4,803 shares in the last quarter. 90.73% of the stock is owned by hedge funds and other institutional investors.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: What is a dividend reinvestment plan?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.